Anatara Lifesciences Expands GaRP-IBS Clinical Trial Sites to Adelaide and Sunshine Coast, Drives Record Enrollments
Anatara Lifesciences (ASX: ANR) is pleased to announce robust progress in recruitment for Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial. ADELAIDE, SA, AUSTRALIA, November 14, 2024 /EINPresswire.com/ -- Anatara Lifesciences (ASX: ANR), …